

The Actuarial Profession
making financial sense of the future

Highlights of the Pensions conference 2010
Daniel Ryan



How long are we going to live?

Insights on the past and future

© 2010 The Actuarial Profession | www.actuaries.org.uk

Breadth of current longevity models


- Extrapolative
 - analysis of historical all-cause mortality experience
 - project past trends on deterministic/stochastic models
 - no explicit constraints placed on model
- Targeting
 - expert opinion or historical trends
- Explanatory
 - cause-specific mortality
 - disease diagnosis, interaction and subsequent death

Fundamental importance of time

- Extrapolative models allow the user to overlook significance of different time periods
- Clear horizons that separate informed opinion from guesswork
- Short to medium term (c. 10 years)
 - predictive scenarios based on clinical guidelines, current treatments & experience in other countries
- Long term
 - historical analysis (adjusted OR unadjusted)
 - impact of changes over short to medium term
 - amenable mortality
 - future advances for particular diseases

The Health Improvement Network data

Content and structure of data CSD EPIC provides to researchers



THIN extract from specimen medical record

- All consultation events are recorded by Doctor in Vision system using Read codes (standardised clinical terms) and drug codes from Multilex and BNF coding systems
- Below is extraction from medical history of chronological events for a 65 year old female with diagnosis of Diabetes and Hypothyroidism

14/01/2000	1013.11	Pain	R		0			
14/01/2000	66U.11	Hormone replacement therapy	R		0			
14/01/2000	88889998	ESTRADIOL+NORETH AC 2 WE	R		0			
14/01/2000	88889998		Y	(50mcg + 170mcg)/24	hr	patch	I	6
14/01/2000	97235998	CO-PROXAMOL	Y	32.5mg + 325mg		tablets		100
14/01/2000	98219994	U100single use	Y	0.5ml		insulin syringe with 12mm needle(26G)		60
14/01/2000	98219994							
18/01/2000	C10.00	Diabetes mellitus	R		0		J	
23/02/2000	91179994	Pocket Scan	Y			biosensor strip(s)		1
23/02/2000	97991996	LEVOTHYROXINE	Y	100micrograms		tablets		100
23/02/2000	98219994	U100single use	Y	0.5ml		insulin syringe with 12mm needle(26G)		60
23/02/2000	98219994					ge injection		5
23/02/2000	98228997	INSULINISOPHANE HUMAN PYR	Y	100 iu/ml				
21/03/2000	171.00	Cough	R		0		I	1
21/03/2000	99930998	IPRATROPIUM BROMIDE	Y	20micrograms/ actuation		aerosol inhaler		1
21/03/2000	99930998							
12/04/2000	C04.13	Hypothyroidism	R		0		I	
12/04/2000	97991997	LEVOTHYROXINE	Y	50micrograms		tablets		100
13/04/2000	1013.11	Pain	R		0		I	
13/04/2000	97126996	IBUPROFEN	Y	600mg		tablets		200
13/04/2000	97235998	CO-PROXAMOL	Y	32.5mg + 325mg		tablets		100
15/05/2000	98219994	U100single use	Y	0.5ml		insulin syringe with 12mm needle(26G)		60
15/05/2000	98219994							
15/05/2000	98228997	INSULINISOPHANE HUMAN PYR	Y	100 iu/ml		ge injection		5
13/06/2000	1013.11	Pain	R		0		I	
13/06/2000	91179994	Pocket Scan	Y			biosensor strip(s)		1
13/06/2000	97126996	IBUPROFEN	Y	600mg		tablets		200
13/06/2000	97991997	LEVOTHYROXINE	Y	100micrograms		tablets		100
13/06/2000	97991997	LEVOTHYROXINE	Y	50micrograms		tablets		100
15/06/2000	R062.00	[D]Cough	R		0		I	
15/06/2000	97131998	AMOXICILLIN	Y	250mg		capsules		21
28/06/2000	171.11	C/O - cough	R		0		I	
28/06/2000	1003050000	Alcohol, Units Drunk Per Week	R		3			136.00

Copyright: CEGEDIM 2009

Disease-based mortality models


- Extension of impaired life annuity concept
- Multi-state model of all-cause mortality
- Remote access or dataset from General Practice Research Database ("GPRD") or The Health Improvement Network ("THIN")
 - identify new disease from "healthy" population
 - track development of subsequent disease
 - track deaths from individuals with prior history of disease
- Two potential approaches to derive future mortality

Framework of TW_DBMMv2.x(y)


Disease Groups	Diseases considered
Minor Group 1 (IG1)	atherosclerosis, cardiac arrhythmias, cardiomyopathy, diabetes, hypercholesterolaemia, hypertension, transient ischaemic attacks, valvular disease
Minor Group 2 (IG2)	benign neoplasms, malignant skin cancers other than malignant melanoma
Minor Group 3 (IG3)	epilepsy, motor neurone disease, MRSA, multiple sclerosis, osteoporosis, osteoarthritis, rheumatoid arthritis
Principal Group 1 (DG1)	stroke
Principal Group 2 (DG2)	cancers of breast, cervix, larynx, prostate and uterus, plus malignant melanoma
Principal Group 3 (DG3)	aneurysms, ischaemic heart disease, heart failure
Principal Group 4 (DG4)	chronic obstructive pulmonary disease, pneumonia and tuberculosis
Principal Group 5 (DG5)	cancers of colon, ovary, rectum and urinary system, plus oral cancers, leukaemias and lymphomas
Principal Group 6 (DG6)	Crohn's disease, gastric and duodenal ulcers, clostridium difficile infection, ulcerative colitis, and kidney and liver disease
Principal Group 7 (DG7)	cancers of brain, lung, oesophagus, pancreas and stomach, and multiple myeloma

Disease-based mortality model

Prevalence of disease – women (2008)



Disease-based mortality model Distribution of deaths – women (2008)



Holistic view of future longevity


- Longevity projectionists – Vaupel/Bongaarts
 - projection of trends without deconstruction
 - no imminent sign of limit to life expectancy
 - future medical advances expected to be as significant as historical advances
- Longevity realists/pessimists – Olshansky
 - question lack of explanation from projectionists
 - stress ageing process as separate from disease
 - no current treatments for ageing process
- Recent convergence on potential scenarios of increases in life expectancy of 7 years by 2050

Predictive scenario on impact of treatment

- National Institute for Clinical Excellence (NICE)
 - Technical Appraisals
 - Clinical Guidance
- TA 176 – cetuximab for combination first-line treatment of KRAS metastatic colorectal cancer by blocking EGFR
 - metastases restricted to liver and unresectable but primary tumour resectable and patient fit enough for surgery
- Target population: 1,402
- Cost per QALY: £30,000
- Total annual cost: £18.8 million
- Average increase in “healthy” life expectancy: 5.3 months

Predictive scenario based on clinical guidelines

- Systolic blood pressure target guidelines:
- Quality Outcome Framework
 - 150mmHg
- Joint British Societies 2
 - 130mmHg
- AHA Strategic Impact Goal through 2020
 - 120mmHg
- Promotion of combination therapy (CG 34)



Source: Health Survey for England (2003)

Fundamental importance of time

- Extrapolative models allow the user to overlook significance of different time periods
- Clear horizons that separate informed opinion from guesswork
- Short to medium term (c. 10 years)
 - predictive scenarios based on clinical guidelines, current treatments & experience in other countries
- **Long term**
 - **historical analysis (adjusted OR unadjusted)**
 - **impact of changes over short to medium term**
 - **amendable mortality**
 - **future advances for particular diseases**

Long-term mortality improvements in CMI Mortality Projection Tool & ONS 2008 projections

- International historical analysis
- Mortality improvement differentials
 - CMI Permanent Assured Lives and CMI Pensioners in UK
- Development of expert opinion for different assumptions in census analyses.
- Relevance of cohort mindset of ONS when developing mortality improvements led to cohort features despite experts' comments.

Origins and uses for amenable mortality

- Deaths occurring before age 75 in diseases regarded as amenable.
- Would include breast cancer, colo-rectal cancer, leukaemia, ulcers and hypertensive diseases
- Key work in recent decades by Nolte & McKee
 - “Measuring the health of nations”
- 43% and 38% reduction in amenable causes of death for men and women respectively over period 1993 to 2005.

Cumulative improvements to mortality predicted over 2008-2020 for ages 70-74

Disease Groups	Male lives	Female lives
Healthy	13.1%	13.1%
Minor Group 1 (IG1)	14.5%	15.3%
Minor Group 2 (IG2)	-3.1%	11.2%
Minor Group 3 (IG3)	12.2%	12.2%
Principal Group 1 (DG1)	16.9%	16.7%
Principal Group 2 (DG2)	30.8%	32.7%
Principal Group 3 (DG3)	18.7%	18.9%
Principal Group 4 (DG4)	9.7%	8.0%
Principal Group 5 (DG5)	23.3%	24.4%
Principal Group 6 (DG6)	12.7%	12.8%
Principal Group 7 (DG7)	12.0%	9.7%
Principal Group 8 (DG8)	12.2%	16.8%
All lives	21.3%	19.5%

Long-term trends in non-smoker mortality

Data sources


- UK Doctor's Study & American Cancer Society – Cancer Prevention Study (2)
 - Excess mortality of smokers over never smokers
 - Reduction in excess mortality for ex-smokers
- General Household Survey
 - Annual survey covering smoking & other behaviours
 - Published data for proportions of smokers, non-smokers and ex-smokers for relatively wide age groups
 - Time Series Dataset includes 800,000 interviews over the period 1972 to 2004
- ONS mortality experience
 - Deaths and population exposure by sex and individual age from 1971 up to age 89

Long-term trends in non-smoker mortality


Model structure

- Population transition model using annual steps designed to derive non-smoker mortality rates from aggregate mortality rates
- Model tracks population exposures from age 20 for smokers, never smokers, former smokers by individual year since cessation up to 15 years & former smokers of 15+ years since cessation
- Resetting to annual population estimates with similar distribution for migrants and residents
- General Household Survey used to set starting distribution and then to validate model outputs
- EXCEL Solver applied to smoker cessation rates


Contribution of changes in smoking prevalence Male aggregate mortality improvements




Contribution of changes in smoking prevalence Effect of changes in smoking prevalence (men)



Comparisons of future assumptions Annuity values @1% for women




Future advances in treating circulatory disease – aortic valve replacement




Trans-aortic

Trans-apical




Patients with symptomatic aortic stenosis who have high risk for operative mortality or are “non-operable”

Future advances in treating circulatory disease – aortic valve replacement




Future advances in treating circulatory disease – Induced pluripotent stem cells




Stem cells derived from adult tissues such as skin fibroblasts

Future advances in treating circulatory disease – self-assembling nanofibres




Segers / Lee
Circulation 2007

Improved function after MI



Davis / Lee PNAS 2006

Comparisons of future assumptions Complete cohort life expectancy for women



Base Table: PNFA00, 75% MC/LC (2008)